Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure

Haematologica

Volumn 98, Issue 2, 2013, Pages

  Prébet, Thomas ^a,b   Thepot, Sylvain ^c   Gore, Steven D ^a   Dreyfus, François ^d   Fenaux, Pierre ^c   Vey, Norbert ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b INSTITUT PAOLI CALMETTES   (France)

^c AVICENNE HOSPITAL   (France)

^d NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; LENALIDOMIDE; THALIDOMIDE; VORINOSTAT; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGE; AGED; ALLOTRANSPLANTATION; CANCER RISK; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; SURVIVAL; TREATMENT OUTCOME; MORTALITY; MYELODYSPLASTIC SYNDROMES; TREATMENT FAILURE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HUMANS; MYELODYSPLASTIC SYNDROMES; TREATMENT FAILURE;

EID: 84875339946     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.071050     Document Type: Letter

References (12)

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodys-plastic syndromes. Blood. 1997;89(6):2079-88.
2. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111(2):574-82.
3. Garcia-Manero G, Fenaux P Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 2011;29(5):516-2
4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
5. Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, et al Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer. 2010;116(6):1485-94
6. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, et al Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009;27(11):1850-6.
7. Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, et al Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322-7.
8. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et alThe 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
9. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671-4.
10. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-65.
11. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, et al Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86-93.
12. Stone RM How I treat patients with myelodysplastic syndroms. Blood. 2009;113:6296-303